Mukul Verma 7/23/24 Mukul Verma 7/23/24

Immunome bets on Nectin’s antibodies for next-generation antibody drug conjugates

The collaboration aligns with Immunome's strategy of pursuing under-explored targets for cancer drugs.

Mukul Verma 12/18/23 Mukul Verma 12/18/23

Nectin Adds Combination Therapy and Expands Clinical Trial Sites

Nectin Therapeutics Adds Combination Therapy Arm and Expands Sites in Phase 1 Clinical Trial of Its First-in-Class Anti-PVR Immune-Oncology Agent.

The Cancer Focus Fund has invested in Nectin Therapeutics

Mukul Verma 5/16/23 Mukul Verma 5/16/23

Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin’s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma

Mukul Verma 11/30/22 Mukul Verma 11/30/22

Israeli biotech company begins trial for cancer immuno-oncology solution

Nectin's product, NTX1088, blocks the harmful overexpression of PVR proteins, which occurs in tumors caused by lung, breast, throat and other cancers.

Mukul Verma 11/30/22 Mukul Verma 11/30/22

Nectin Announces Extended Series A Financing to Over $25M and Start of Patient Dosing in Phase 1 Clinical Trial of First-in-Class Immunotherapy for Treatment of Patients with Advanced Solid Tumors

Mukul Verma 3/7/22 Mukul Verma 3/7/22

Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy